You are here

Researchers Find Bias and Selective Reporting in Surgical Clinical Studies

Surgical journals more at fault than medical journals (Mar. 14)

According to a recent Reuters report, drug trials aren’t the only studies that can be clouded by selective reporting of positive results. Researchers in the Netherlands have found that trials of surgical treatments can be even more biased. Their study was published in the Annals of Surgery.

The authors’ objective was to compare the primary outcomes specified in trial registries with those reported in published papers to determine whether outcome-reporting bias favored significant outcomes. Outcome-reporting bias was defined as the selective reporting of a subset of original registered outcome measures based on their results.

In a PubMed search, the investigators identified 327 surgical randomized controlled trials (RCTs) indexed between 2007 and 2012 in 10 surgical journals and 10 general medical journals. They found that registration was lacking for 109 (33%) of these papers — 107 (98%) in surgical journals and two (2%) in medical journals.

Twelve trials (6%) were still recruiting patients at the time of publication, and 48 (22%) were registered after the study was completed. Only 152 studies (46%) were registered before the end of the trial, with the primary outcome clearly specified. Of these papers, the authors found that 75 (49%) showed evidence of discrepancies between registered and published outcomes, most often related to the omission of a stated primary outcome or the introduction of a new one. These discrepancies favored statistically significant results in 28% of the papers.

The authors concluded that the quality of registration of surgical trials published in surgical journals was inferior to those published in general medical journals. Moreover, surgical journals were more likely to feature selective outcome reporting.

According to the Reuters report, incomplete or modified publication of clinical trial results can have serious consequences, including the promotion of ineffective or harmful treatments, or the use of expensive therapies when cheaper, more effective alternatives are available.

Sources: Reuters; March 14, 2013; and Annals of Surgery; February 12, 2013.

Recent Headlines

Two-Thirds of U.S. Alzheimer’s Cases Are Women, And It’s Not Just Because They Live Longer
Recarbrio Should be Reserved For Limited/No Alternative Antibacterial Treatment Cases
Breast Cancer, Gastrointestinal Tumors Most Common Types
NY Hospitals Required to Implement Protocols in Suspected Cases
Presence of BOK Protein Key for Positive Treatment Response
Patient Access to Inhaler Use Data Could Improve Asthma Management
Primary Immunodeficiencies Affect 250,000 People in U.S.